Vaxcyte Doses First Participant in Phase 1 Study for VAX-A1 Strep Vaccine, Targeting Major Unmet Need
PCVX sits 63% above its 52-week low of $29.08.
Summary
Vaxcyte has dosed the first participant in its Phase 1 study for VAX-A1, an investigational vaccine candidate targeting Group A Streptococcus. This marks the entry of a new program into clinical trials, diversifying Vaxcyte's pipeline beyond its lead VAX-31 pneumococcal vaccine, which recently completed Phase 3 enrollment. Group A Strep is responsible for a significant global disease burden with no approved vaccine, indicating a large potential market for a successful preventative solution. Topline data from this Phase 1 study is anticipated in the second half of 2027.
At the time of this announcement, PCVX was trading at $47.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $29.08 to $65.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.